# Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

> **NCT02349906** · PHASE2 · COMPLETED · sponsor: **medac GmbH** · enrollment: 106 (actual)

## Conditions studied

- Primary Immunodeficiencies
- Inborn Errors of Metabolism
- Haemoglobinopathies
- Bone Marrow Failure Syndromes

## Interventions

- **DRUG:** Treosulfan
- **DRUG:** Busilvex

## Key facts

- **NCT ID:** NCT02349906
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2020-05-07
- **Final completion:** 2023-02-13
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349906, "Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02349906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*